Skip to content
Medical Health Aged Care

Envision Pharma Group Welcomes Industry Veteran and HR Expert Carolyn Bartholdson as Chief People Officer

Envision Pharma Group 2 mins read

Carolyn's strategic vision and experience will be integral to securing and creating top talent to advance Envision's priorities.

FAIRFIELD, CT / ACCESSWIRE / January 18, 2024 / Envision Pharma Group (Envision) has appointed Carolyn Bartholdson as its new Chief People Officer and member of the Executive Leadership Team.

Envision Pharma Group logo
Envision Pharma Group logo

"We are thrilled to welcome Carolyn, who's proven herself as a people-leading expert in the life sciences industry, to Envision as our new Chief People Officer," says Howard Miller, CEO of Envision Pharma Group. "Her strategic vision aligns seamlessly with ours, and her exceptional leadership experience will play a crucial role in securing and retaining top talent to support our growth."

Carolyn's extensive experience and industry background were most recently put to use in her Chief Human Resources role at Omnicom Health Group, where she led a global team overseeing human resources strategy and operations for the healthcare division of Omnicom. In this role, Carolyn completed multiple company HR integrations and created a mobility program to retain top talent. Her additional experience leading global company initiatives includes leadership roles with Pfizer, Barclays Wealth, and QBE North America.

"I am excited to bring my talents to such an innovative and progressive company as Envision Pharma Group," adds Carolyn. "This is a unique opportunity for me to help accelerate the trajectory of an incredibly talented group of smart and dynamic individuals in the life sciences, an industry I love."

About Envision Pharma Group:

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information:

Colleen Carter
Associate Director, Communications, Office of CEO
[email protected]
1 (508) 505 8856

SOURCE: Envision Pharma Group

.

View the original press release on newswire.com.

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.